Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients

Moon, Joon Ho; Sohn, Sang Kyun; Kim, Shi Nae; Park, Seon Yang; Yoon, Sung Soo; Kim, In Ho; Kim, Hyeoung Joon; Kim, Yeo Kyeoung; Min, Yoo Hong; Cheong, June Won; Kim, Jin Seok; Jung, Chul Won; Kim, Dong Hwan

doi:10.1007/s12032-011-9926-8

Cited by 37 publications

(90 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eight publications came from Europe, 14,15,18,19,21,24,25,30 5 from the US, 20,23,[31][32][33] 5 from Asia 22,26,28,29,35 and one from Australia.…”

Section: Literature Searchmentioning

confidence: 99%

“…27 If a diagnosis code was used, it was based on ICD9 for CML patients. In 8 (42%) studies, patients were in CML-CP, 15,18,21,22,24,26,28,35 and in a further 2 studies patients could be in any of the 3 CML phases. 14,32 The disease duration varied across studies, ranging from less than three months to five years.…”

Section: Patients' Characteristics and Treatmentmentioning

confidence: 99%

“…An overview of the included articles is given in Online Supplementary Table S3. 14,15, Only 19 peer review articles were analyzed and reported in the Results section.Eight publications came from Europe, 14,15,18,19,21,24,25,30 5 from the US, 20,23,[31][32][33] 5 from Asia 22,26,28,29,35 and one from Australia.27 Almost half of the included studies were retrospective (9 of 19) and mainly conducted in the US and Asia 38,41,42,45,49,52,53 while half of the European studies were prospective (4 of 8). 14,15,18,24 …”

mentioning

confidence: 99%

“…Missing patient and/or treatment data prevented a full interpretation of certain studies on adherence, especially those attempting to compare adherence between medications. 20,22,23,[26][27][28][29]31,32,35,52 It appears that adherence is superior in patients taking 2 nd generation BCR-ABL inhibitors compared with imatinib, as presented in 2 conference abstracts from the literature. 36,43 Contradictory conclusions on adherence across 2 nd generation drugs were observed in this review.…”

mentioning

confidence: 99%

“…In 8 (42%) studies, patients were in CML-CP, 15,18,21,22,24,26,28,35 and in a further 2 studies patients could be in any of the 3 CML phases.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

et al. 2014

View full text Add to dashboard Cite

Correspondence: Lucien.Noens@uzgent.be BCR-ABL inhibitors for treating chronic myeloid leukemia in chronic phase have transformed a previously incurable malignancy into a manageable condition. However, suboptimal medication adherence has been observed with these agents affecting clinical outcomes and healthcare costs. In order to raise awareness of the problem of adherence, and before developing pragmatic strategies to enhance medication adherence, a deep understanding of the best approaches for measuring adherence in chronic myeloid leukemia patients and identifying non-adherence is required. A systematic literature review on the prevalence, measurement methods, consequences and risk factors for non-adherence to BCR-ABL inhibitors and adherence-enhancing interventions was performed and critically appraised. Of the 19 included articles, 9 were retrospective. Average adherence varied from 19% to almost 100% of the proportion of prescribed drug taken, but it was measured through various different methods and within different study groups. Suboptimal adherence was associated with a negative impact on both clinical and economic outcomes. There is a lack of supportive evidence demonstrating a difference in adherence across BCR-ABL inhibitors and even contradictory results between the 2 nd generation inhibitors. Drug-related adverse events and forgetfulness were common reasons for intentional and unintentional non-adherence, respectively, but further research is required to identify additional reasons behind non-adherence or patients at risk of non-adherence. Non-adherence in chronic myeloid leukemia patients treated with BCR-ABL inhibitors is common and associated with critical outcomes. However, this review highlights important existing gaps, reveals inconsistent definitions, and a lack of standardized methods for measuring adherence in chronic myeloid leukemia. All require further investigation. ABSTRACT © F e r r a t a S t o r t i F o u n d a t i o nAnalyses statement for systematic reviews. 16 Publication database (EMBASE, PubMed, and Cochrane Library) specific search terms consisted of both single and MeSH terms for the disease, adherence and BCR-ABL inhibitor therapy (Online Supplementary Table S1). The last search was conducted on December 20 th , 2011. Full-text references were provided for the eligible abstracts that were published after completion of the search process and the analyses. In addition, and due to the lack of existing evidence of adherence in CML, clinical and economic conference proceedings were also searched with a time limit of three years. Preliminary inclusion (or exclusion) of a specific study or conference abstract was based on review of the title and abstract by 2 independent reviewers against pre-specified criteria (Table 1). Final inclusion of the study was based on an in-depth review of the full manuscript. Multiple variables were extracted from the articles to answer study objectives (Online Supplementary Table S2). The analysis was descriptive only. Since abstracts in conference pr...

show abstract